Determination of levetiracetam by GC-MS and effects of storage conditions and gastric digestive systems on drug samples

Basit Öğe Kaydı
dc.authoridERULAS, FATIH AHMET/0000-0002-3506-6881
dc.authoridCHORMEY, DOTSE SELALI/0000-0002-7412-7800
dc.contributor.authorErulas, Fatih Ahmet
dc.contributor.authorChormey, Dotse Selali
dc.contributor.authorOz, Ersoy
dc.contributor.authorBakirdere, Sezgin
dc.date.accessioned2024-12-24T19:32:52Z
dc.date.available2024-12-24T19:32:52Z
dc.date.issued2021
dc.departmentSiirt Üniversitesi
dc.description.abstractBackground: Epilepsy is a neurologic condition that is occurs globally and is associated with various degrees of seizures. Levetiracetam is an approved drug that is commonly used to treat seizures in juvenile epileptic patients. Accurate quantification of the drug's active compound and determining its stability in the stomach after oral administration are important tasks that must be performed. Results & methodology: Levetiracetam was extracted from drug samples and quantified by gas chromatography mass spectrometry using calibration standards. Stability of levetiracetam was studied under various storage conditions and in simulated gastric conditions. The calibration plot determined for levetiracetam showed good linearity with a coefficient of determination value of 0.9991. The limits of detection and quantification were found to be 0.004 and 0.014 mu g center dot ml(-1), respectively. The structural integrity of levetiracetam did not change within a 4-h period under the simulated gastric conditions, and no significant degradation was observed for the different storage temperatures tested. Discussion & conclusion: An accurate and sensitive quantitative method was developed for the determination of levetiracetam in drug samples. The stability of the drug active compound was monitored under various storage and gastric conditions. The levetiracetam content determined in the drug samples were within +/- 10% of the value stated on the drug labels.
dc.identifier.doi10.4155/bio-2021-0258
dc.identifier.endpage222
dc.identifier.issn1757-6180
dc.identifier.issn1757-6199
dc.identifier.issue4
dc.identifier.pmid35014882
dc.identifier.scopus2-s2.0-85124437714
dc.identifier.scopusqualityQ2
dc.identifier.startpage217
dc.identifier.urihttps://doi.org/10.4155/bio-2021-0258
dc.identifier.urihttps://hdl.handle.net/20.500.12604/7836
dc.identifier.volume14
dc.identifier.wosWOS:000741059500001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherNewlands Press Ltd
dc.relation.ispartofBioanalysis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241222
dc.subjectepilepsy
dc.subjectGC-MS
dc.subjectlevetiracetam
dc.subjectsimulated gastric conditions
dc.titleDetermination of levetiracetam by GC-MS and effects of storage conditions and gastric digestive systems on drug samples
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu